Easywell Biomedicals, Inc. (1799) Stock Price & Analysis
1799 Stock Chart & Stats
- Day’s Range
- TWD 24.00 - TWD 25.20
- 52-Week Range
- TWD 24.00 - TWD 44.90
- Previous Close
- TWD 25.45
- Volume
- N/A
- Average Volume (3M)
- 125.55K
- Market Cap
- TWD 6.16B
- Enterprise Value
- TWD 3.80B
- Total Cash (Recent Filing)
- TWD 484.70M
- Total Debt (Recent Filing)
- TWD 386.54M
- Price to Earnings (P/E)
- ―
- Beta
- 0.50
- Next Earnings
- Nov 17, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 26, 2010
- Dividend Yield
- N/A
1799 FAQ
What was Easywell Biomedicals, Inc.’s price range in the past 12 months?
What is Easywell Biomedicals, Inc.’s market cap?
When is Easywell Biomedicals, Inc.’s upcoming earnings report date?
How were Easywell Biomedicals, Inc.’s earnings last quarter?
Is Easywell Biomedicals, Inc. overvalued?
Does Easywell Biomedicals, Inc. pay dividends?
What is Easywell Biomedicals, Inc.’s EPS estimate?
How many shares outstanding does Easywell Biomedicals, Inc. have?
What happened to Easywell Biomedicals, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Easywell Biomedicals, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Easywell Biomedicals, Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; TLX-47, an anti-inflammatory drug; and TLX-024, an anticonvulsant. It also develops TWB-201 for Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company provides thermometers, medical devices, and health food and products. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Ai Ping Lee
- Employees
- 3,118
- Website
- www.easywellbio.com
- Address
- No.10, Yanfa 2nd Road, Hsinchu City, TPE, 30076, TW
Easywell Biomedicals, Inc. (1799) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |

